Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · October 17, 2024

Association of BMI, Lipid-Lowering Medication, and Age With Prevalence of Type 2 Diabetes in Adults With Heterozygous Familial Hypercholesterolaemia

The Lancet Diabetes & Endocrinology

 

Additional Info

The Lancet Diabetes & Endocrinology
Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study
Lancet Diabetes Endocrinol 2024 Oct 03;[EPub Ahead of Print], European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (EAS FHSC)

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading